findmyKOL
Clinical trialNCT07089992RecruitingPhase 2Interventional

A Study of Pembrolizumab in People With Ultra-Rare Sarcomas

SponsorMemorial Sloan Kettering Cancer CenterEnrollment32Sarcoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma. The researchers will also study how the immune system responds to the study treatment. Pembrolizumab is a type of drug called a PD-1 inhibitor. It is designed to block a protein called programmed cell death protein 1 (PD-1) that usually acts as a "brake" on the immune system. Blocking this protein is like releasing the brakes, so that the immune system can target cancer cells and destroy them.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering at Basking Ridge (all Protocol Activities)

    Basking Ridge, New Jersey, United States

    Recruiting
  • Memorial Sloan Kettering Monmouth (limited Protocol Activities)

    Middletown, New Jersey, United States

    Recruiting
  • Memorial Sloan Kettering Bergen (limited Protocol Activities)

    Montvale, New Jersey, United States

    Recruiting
  • Memorial Sloan Kettering Cancer Center Suffolk- Commack (limited Protocol Activities)

    Commack, New York, United States

    Recruiting
  • Memorial Sloan Kettering at Westchester (limited Protocol Activities)

    Harrison, New York, United States

    Recruiting
  • Memorial Sloan Kettering Cancer Center (all Protocol Activities)

    New York, New York, United States

    Recruiting
  • Memorial Sloan Kettering Nassau (all Protocol Activities)

    Uniondale, New York, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
4 Dec 2025
Primary completion
31 Dec 2028
Completion
31 Dec 2028
Last update posted
28 Jul 2026
Registered enrollment
32
Registry id
NCT07089992
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.